Effectiveness of drug therapies to treat or prevent respiratory syncytial virus infection-related morbidity

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.4, Iss.10, 2003-10, pp. : 1801-1808

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging drugs for respiratory syncytial virus infection

By Olszewska Wieslawa Openshaw Peter

Expert Opinion on Emerging Drugs, Vol. 14, Iss. 2, 2009-06 ,pp. : 207-217

Informa Healthcare

Access to resources Recommend Favorite

Respiratory Syncytial Virus Infection in Elderly Adults

By Falsey Ann R. Walsh Edward E.

Drugs & Aging, Vol. 22, Iss. 7, 2005-01 ,pp. : 577-587

Adis International

Access to resources Recommend Favorite

Respiratory Syncytial Virus Infection in Adult Populations

Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol. 12, Iss. 2, 2012-04 ,pp. : 98-102

Bentham Science Publishers

Access to resources Recommend Favorite

Cost Effectiveness of Respiratory Syncytial Virus Prophylaxis: A Critical and Systematic Review

By PrescottJr William A. Doloresco Fred Brown Jack Paladino Joseph A.

PharmacoEconomics, Vol. 28, Iss. 4, 2010-04 ,pp. : 279-293

Adis International

Access to resources Recommend Favorite

Immune-mediated disease pathogenesis in respiratory syncytial virus infection

By Graham B.S. Johnson T.R. Peebles R.S.

Immunopharmacology, Vol. 48, Iss. 3, 2000-07 ,pp. : 237-247

Elsevier

Access to resources Recommend Favorite